Monsanto Roundup Lawsuit

Tuesday, April 07, 2009

Martin Keller to step down in June

"Keller not only failed to disclose the millions of dollars he has received over the years from drug companies whose drugs he was studying and promoting in medical journals and at conferences. But there is evidence that Keller and his co-authors misrepresented data in a clinical trial of Paxil to make the antidepressant look safer and more effective than it really was. This trial, known as study 329 and funded by GlaxoSmithKline, was published in 2001 and used by the drug company to heavily market Paxil for off-label use in children and adolescents. Yet as it turns out, the data in this trial do not corroborate the company's claims that Paxil was more effective than a placebo or sugar pill in treating depression in adolescents."



'Side Effects' author, Alison Bass writes on her excellent blog, that Brown University's, Martin Keller, is to step down from his position in June of this year.

Keller's name is synonymous in the Seroxat world for his input [or rather lack of it] in the Paxil 329 studies.

Read Alison's scoop here.

Fid


Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman

SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING

Post a Comment